DanCann Pharma A/S: Tetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer Pain
COPENHAGEN, Denmark, 11 May 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma”) hereby on behalf of Tetra Bio-Pharma Inc. (“Tetra” or “the Company”), announce the acceleration of a revolutionary Phase 2 clinical trial, PLENITUDE©, to evaluate the safety and efficacy of the investigational cannabis medicine, QIXLEEF™, for use in managing uncontrolled pain in patients with advanced cancer.DanCann Pharma signed May 5th a definitive distribution agreement with Canadian Tetra Bio-Pharma Inc. concerning the exclusive distribution of the cannabinoid-based medicines Reduvo™ Adversa® and